BioSpace News Archive

Bristol-Myers Squibb Company (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced positive top-line results from KarMMa, a pivotal, open-label, single arm, multicenter, Phase 2 study of idecabtagene vicleucel (ide-cel; bb2121).

Almac Group, the global contract development and manufacturing organisation, is delighted to announce it has won the “Innovation in Sponsorship” award during this year’s Irish Sponsorship Awards ceremony in Dublin.

BrainCo’s prosthetic hand won Time Magazine’s Top 100 Inventions of the Year.

Helix BioPharma Corp., an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced the voting results of the Company’s annual and special meeting of shareholders held on December 6, 2019.

Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”) today announced that the Company’s social media campaign for XYOSTED®, has been honored with a 2019 MarCom Platinum Award.

Global Cord Blood Corporation, China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, reported that China’s National Health Commission recently issued a new policy allowing the relevant Provincial Health Commissions to approve cord blood bank licenses in 18 pilot Free Trade Zones in China.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced preliminary tolerability and PK data from its ongoing Phase 1 dose-finding study of fimepinostat, a small molecule dual inhibitor of PI3K/HDAC and suppressor of MYC, in combination with venetoclax,

3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation for AuriNovo™, an investigational combination product for reconstruction of the outer ear in patients with microtia.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that the first patient in the global Phase 2 registration-enabling study of RP-L102 “Process B” received investigational therapy.

Investor and analyst event to be held on Monday, December 9, 2019 at 7:30 PM ET at the Hyatt Regency Orlando featuring a fireside chat with leading clinical investigators